Dermatomyositis and myelodysplastic syndrome with myelofibrosis responding to methotrexate therapy.
Dermatomyositis (DM) has not yet been reported as a complication of myelodysplastic syndrome (MDS). A 50-year-old man was diagnosed as having MDS because of the presence of anemia, the appearance of immature cells in peripheral blood, and the abnormal cellular morphology. A few months later, high fever, myalgia and erythema developed. Although DM symptoms were resistant to high-dose corticosteroid administration, methotrexate (MTX) therapy improved not only the symptoms of DM but also hematologic findings related to MDS. This indicates that immunosuppressive therapy including MTX administration can be useful for patients with MDS with autoimmune symptoms.
Tsuji
Goh
G
Division of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
Maekawa
Soichiro
S
Saigo
Katsuyasu
K
Nobuhara
Yumiko
Y
Nakamura
Tomoko
T
Kawano
Seiji
S
Koshiba
Masahiro
M
Asahara
Shunichiro
S
Chinzei
Tadanobu
T
Kumagai
Shunichi
S
D001773:Blood Cells / Q000473:pathology; D001854:Bone Marrow Cells / Q000473:pathology; D003882:Dermatomyositis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D055728:Primary Myelofibrosis / Q000209:etiology / Q000473:pathology; D016896:Treatment Outcome
D008727:Methotrexate